SynChem (China), Ltd established its new laboratory in Shanghai, China.
Oct 10, 2003
SynChem (China), Ltd, a branch company of Chicago-based SynChem, Inc, established its new 12,500 sq. ft. laboratory in Shanghai, China. This expands the facility to a total of 25,000 sq. ft. and is fully equipped and functional laboratory capable of production to kilogram scale. By combining its Chicago-based laboratory and Shanghai-based laboratory SynChem can offer its full spectrum service to its customers, ranging from time-sensitive projects to cost-sensitive projects. Through integration of its two sites SynChem continues its commitment to become a powerhouse in an organic synthesis for its customers, including drug discovery, biotech, and pharmaceutical companies.
|
SynChem, Inc. and Helicon Therapeutics, Inc. sign collaborative research agreement for process research chemistry
June 20, 2003 (see story from biospace)
Helicon
Therapeutics, Inc. and SynChem, Inc. today announced that they
have signed an agreement for the process research chemistry for one of
Helicon’s development compounds. Under the terms of the agreement, SynChem
will combine its expertise in the organic synthesis with Helicon’s
proprietary drug lead for the treatment of disorders of cognitive function
related to memory. Both companies will contribute unique, chemical
expertise to the Collaboration. Helicon has a research program based on
CREB activation, which serve as target for the identification of novel
therapeutics for memory loss. "We are delighted to initiate this process
research chemistry collaboration with Helicon. We look forward to
achieving success on behalf of Helicon and growing our company with
Helicon whom we can provide this very valuable organic chemistry service”
said Dr. W. Paul Mar, President and CEO of SynChem, Inc.
|
|
|
SynChem, Inc. and Neurocrine Biosciences, Inc. signed a extended collaboration agreement for combinatorial chemistry
May 1, 2003 (see story from biospace)
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and SynChem, Inc. today announced that they have signed an extended agreement for the design and synthesis of a combinatorial chemistry template around small molecules targeted at the super-family of receptors called G protein coupled receptors (GPCRs). Neurocrine decided that it would extend Year 2002 agreement because SynChem has reached the research milestones setup by Neurocrine. Under the terms of the agreement, SynChem will continue its research program for Neurocrine and combine its expertise in the synthesis of new combinatorial chemistry templates with Neurocrine’s computational methodology and high throughput synthesis to design and synthesize a library targeted at GPCRs. Neurocrine has several research programs based on GPCRs, which serve as targets for the identification of novel therapeutics. "The signing of this extended agreement is a significant achievement for SynChem, Inc. Year 2002 deal was our first with a major drug discovery company. Its success validates our strategy of utilizing SynChem’s organic synthesis expertise in the discovery of innovative new drugs - confirming our unique position in this rapidly advancing area of drug discovery," said Dr. W. Paul Mar, President and CEO, SynChem, Inc. "I am very pleased that we can finish the first program for Neurocrine in less than half year and has the opportunity to sign this deal with Neurocrine, which has a long track record of success in developing new drugs. “Neurocrine remains committed to the design and synthesis of small, focused libraries for particular families of molecular targets. Synchem provides an expert group who have repeatedly met collaboration objectives which, in turn, allows us to synthesize such libraries in a very efficient manner” said John Saunders, Ph.D. Vice President of Research Chemistry for Neurocrine Biosciences.
|
|
|